Amo Corporation — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$336,807	5
2024	Research	$371,208	3
2021	Research	$2,550	1
2020	Research	$27,615	4
2019	Research	$120,986	3

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $708,014 8 payments
Biogen, Inc. $104,440 3 payments
Ucb SA $39,898 3 payments
Pfizer Inc. $6,788 1 payment
Mallinckrodt Enterprises LLC $25 1 payment

Studies the money was for Research payments · program years 2019–2025

An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $660,450 4 payments
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy $104,440 3 payments
A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy $34,258 1 payment
A Two Year Double Blind Randomized Multicenter Active Controlled Study to Evaluate the Safety and Efficacy of Fingolimod Administered Orally Once Daily Versus Interferon Beta 1A I M Once Weekly in Pediatric Patients With Relapsing Remitting Multiple Sclerosis $13,986 1 payment
A Single-Arm, Prospective, Multi-Center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-Cd20 Monoclonal Antibody (Acd20 Mab) Therapy (Olikos) $13,310 1 payment
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R $10,334 1 payment
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light $9,934 1 payment
A 12Month Openlabel Study to Evaluate the Safety and Tolerability of Pregabalin As Adjunctive Therapy in Pediatric Subjects 1 Month to 16 Years of Age With Partial Onset Seizures and Pediatric and Adult Subjects 5 to 65 Years of Age With Primary Generalized Tonicclonic Seizures $6,788 1 payment
A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal Onset Seizures in Adult $5,640 2 payments
A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar Gel in the Subjects With Relapsing-Remitting Multiple Sclerosis $25 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.